

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Obinutuzumab with mycophenolate mofetil for treating lupus nephritis

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Final draft guidance

(when no draft guidance was issued)

1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how?

The scope EIA noted several issues including:

- Higher prevalence in people of Indo-Asian, African, Caribbean, and Chinese heritage and potential for differences in efficacy of obinutuzumab in those groups
- Higher prevalence in women (although noting that men may be more likely to present with more severe disease and progress quicker)
- Poor maternal and foetal outcomes for pregnant people with lupus nephritis
- Health inequities related to access to current treatment, including those for people with lower socioeconomic status
- Noting kidney disease (which may result from lupus nephritis) is more prevalent, faster progressing, and potentially receiving lower care quality in some groups protected by the Equalities Act.

The committee considered the differences in prevalence in protected groups and the poorer outcomes in pregnant people during deliberations of

equalities issues. The committee considered equity of access in its deliberations of uncaptured benefits.

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these?

No other equalities issues identified

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

N/A

4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No

5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

N/A

7. Have the committee's considerations of equality issues been described in the final draft guidance, and, if so, where?

Yes, in section 3.14 of the FDG

Approved by Associate Director (name): Ross Dent

Date: 08/01/2026

Technology appraisals: Guidance development

Equality impact assessment for the single technology appraisal of Obinutuzumab with mycophenolate mofetil immunosuppressive therapies for treating lupus nephritis